Thalia Therapeutics Plc — Lipisiran™ cardiovascular in vitro study completed

Thalia advances Lipisiran™ to animal studies after all constructs hit targets in vitro.

What the company is saying

Thalia Therapeutics plc reports that its Lipisiran™ (THAT-002) in vitro study is complete, with all four constructs (100%) successfully engaging their intended targets. The company highlights that these constructs lowered both PCSK9 and Lp(a) as effectively as individual siRNA sequences, meeting the study's objectives. Management positions Lipisiran™ as a dual-target, long-duration siRNA, suggesting it could reduce heart attack and stroke risk. The announcement emphasizes that in vivo studies have now commenced, marking progression in the development pipeline. To underscore market relevance, Thalia references Merck KGaA’s proposed US$1.3 billion acquisition of Silence Therapeutics, framing this as evidence of strong industry interest in next-generation siRNA Lp(a) therapeutics. The tone is confident and forward-looking, focusing on scientific achievement and commercial potential. No financial or operational results specific to Thalia are disclosed. The company does not provide timelines for clinical development or regulatory milestones.

What the data suggests

The in vitro study tested four Lipisiran™ constructs, all of which (100%) engaged their molecular targets and reduced both PCSK9 and Lp(a) to the same extent as individual siRNA sequences. This technical success allows the program to move into in vivo (animal) studies, which have already begun. No data is provided on the duration of effect, pharmacokinetics, or safety, so the 'long-duration' claim remains unsubstantiated by disclosed evidence. The only numerical financial figure is the US$1.3 billion proposed acquisition value for Silence Therapeutics by Merck KGaA, which is external to Thalia and serves as a sector benchmark rather than a direct valuation or funding event for Thalia itself. The company does not disclose any Thalia-specific financials, clinical timelines, or animal data. The evidence presented is limited to preclinical in vitro results, with no indication yet of efficacy or safety in animals or humans. The announcement is a standard R&D milestone update, not a commercial or financial inflection point.

Analysis

The announcement presents a positive tone, highlighting the successful completion of an in vitro study and the initiation of in vivo studies for Lipisiran™. The realised progress is limited to preclinical laboratory results (in vitro), with no in vivo, clinical, or financial outcomes disclosed. Management's framing of Lipisiran™ as a 'potential means to reduce heart attack and stroke risk' is aspirational, as no efficacy data in animals or humans is provided. The reference to Merck KGaA’s proposed acquisition of Silence Therapeutics is used to imply market validation, but this is an external event and does not directly reflect Thalia Therapeutics plc’s own progress or value. The majority of claims are factual regarding the in vitro study, but the leap to cardiovascular risk reduction is not yet substantiated. No capital outlay or immediate financial impact is disclosed, and the benefits of the program, if any, are likely several years away.

Risk flags

• ●The transition from in vitro to in vivo studies introduces significant biological and translational risk, as many compounds that succeed in vitro fail to demonstrate efficacy or safety in animal models. This matters because the current evidence is limited to laboratory assays, and no animal or human data are available.
• ●The company's claim that Lipisiran™ could reduce heart attack and stroke risk is not supported by any disclosed preclinical or clinical outcome data. This introduces a risk of overstatement and may set unrealistic expectations for investors regarding the timeline and probability of clinical success.
• ●No Thalia-specific financial data, funding status, or development timeline is disclosed, making it difficult for investors to assess the company's ability to finance continued R&D or withstand potential setbacks. This opacity increases uncertainty around execution and capital requirements.
• ●The reference to Merck KGaA’s proposed US$1.3 billion acquisition of Silence Therapeutics is used to imply market validation, but this external event does not guarantee demand or value for Thalia’s own assets. Relying on sector transactions as a proxy for internal progress can mislead investors about the company's actual position.

Bottom line

Thalia Therapeutics plc has completed a key preclinical milestone, with all four Lipisiran™ constructs demonstrating target engagement and biomarker reduction in vitro, enabling the start of animal studies. The announcement is scientifically credible at the laboratory stage but does not provide data on duration of effect, safety, or in vivo efficacy, so the broader therapeutic claims remain unproven. The reference to Merck KGaA’s proposed US$1.3 billion acquisition of Silence Therapeutics highlights sector interest but does not translate into immediate value or validation for Thalia. Investors should recognize that the program is still at an early preclinical stage, with years of development and substantial risk ahead before any potential clinical or commercial payoff. The most important takeaway is that Lipisiran™ has cleared its first technical hurdle, but the path to value creation remains long and uncertain, with no new financial or operational disclosures to clarify funding or timelines.

Announcement summary

(LSE:THAT) Thalia Therapeutics plc announced the successful completion of the Lipisiran™ (THAT-002) in vitro study. The study tested all four constructs of Lipisiran™, with 100% of constructs engaging their targets. The constructs were shown to lower both PCSK9 and Lp(a) as effectively as individual siRNA sequences. The study met its objectives, enabling progression to in vivo studies, which have now commenced. Management described Lipisiran™ as a dual-target, long-duration siRNA. The company stated that this approach could potentially reduce heart attack and stroke risk. Thalia Therapeutics plc referenced Merck KGaA’s proposed acquisition of Silence Therapeutics as evidence of strong market interest in next-generation siRNA Lp(a) therapeutics. The proposed acquisition of Silence Therapeutics by Merck KGaA is valued at approximately US$1.3 billion. The announcement highlights the relevance of Lipisiran™ in the context of industry developments. The company emphasized the effectiveness of its constructs in achieving the intended biological effects. The in vitro study results support further development of Lipisiran™. The company has now initiated in vivo studies following the successful in vitro results. The announcement positions Lipisiran™ as a potential new therapeutic for cardiovascular risk reduction. The company’s management framed the results as a significant milestone for the Lipisiran™ program.

Disagree with this article?